title: Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum.
abstract: Success in pharmaceutical development led to a record 51 drugs approved in the past year, surpassing every previous year since 1950. Technology innovation enabled identification and exploitation of increasingly precise disease targets ensuring next generation diagnostic and therapeutic products for patient management. The expanding biopharmaceutical portfolio stands, however, in contradistinction to the unsustainable costs that reflect remarkable challenges of clinical development programs. This annual Therapeutic Innovations issue juxtaposes advances in translating molecular breakthroughs into transformative therapies with essential considerations for lowering attrition and improving the cost-effectiveness of the drug-development paradigm. Realizing the discovery-translation-application continuum mandates a congruent approval, adoption, and access triad.
authors.affiliation: Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Waldman
authors.affiliation: Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: A
authors.initials: A
authors.lastname: Terzic
mesh_terms: D003362:Cost-Benefit Analysis; D004059:Diffusion of Innovation; D017277:Drug Approval / Q000706:statistics & numerical data*; D015195:Drug Design; D055808:Drug Discovery / Q000191:economics / Q000639:trends*; D006801:Humans; D057170:Translational Research, Biomedical / Q000191:economics / Q000639:trends*